MIM
RCUS icon

MetLife Investment Management’s Arcus Biosciences RCUS Stock Holding History

MetLife Investment Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$968K Buy
44,809
+1,375
+3% +$29.7K ﹤0.01% 1413
2025
Q4 		$1.04M Buy
43,434
+1,972
+5% +$40.2K 0.01% 1410
2025
Q3 		$564K Hold
41,462
– – ﹤0.01% 1750
2025
Q2 		$338K Buy
41,462
+8,451
+26% +$72.2K ﹤0.01% 1883
2025
Q1 		$259K Sell
33,011
-514
-2% -$5.96K ﹤0.01% 2060
2024
Q4 		$499K Buy
33,525
+2,521
+8% +$41.2K ﹤0.01% 1797
2024
Q3 		$474K Hold
31,004
– – ﹤0.01% 1815
2024
Q2 		$472K Buy
31,004
+2,870
+10% +$46.3K ﹤0.01% 1747
2024
Q1 		$531K Hold
28,134
– – ﹤0.01% 1640
2023
Q4 		$537K Hold
28,134
– – ﹤0.01% 1644
2023
Q3 		$505K Hold
28,134
– – ﹤0.01% 1629
2023
Q2 		$571K Buy
28,134
+1,203
+4% +$22.9K ﹤0.01% 1610
2023
Q1 		$491K Hold
26,931
– – ﹤0.01% 1654
2022
Q4 		$557K Buy
26,931
+480
+2% +$13.2K ﹤0.01% 1573
2022
Q3 		$692K Hold
26,451
– – 0.01% 1404
2022
Q2 		$670K Buy
26,451
+1,412
+6% +$34.6K 0.01% 1461
2022
Q1 		$790K Buy
25,039
+9,127
+57% +$306K 0.01% 1475
2021
Q4 		$644K Hold
15,912
– – 0.01% 1367
2021
Q3 		$555K Sell
15,912
-2,486
-14% -$77.4K 0.01% 1463
2021
Q2 		$505K Hold
18,398
– – ﹤0.01% 1561
2021
Q1 		$517K Hold
18,398
– – ﹤0.01% 1504
2020
Q4 		$478K Hold
18,398
– – ﹤0.01% 1512
2020
Q3 		$315K Buy
18,398
+2,753
+18% +$61.5K ﹤0.01% 1603
2020
Q2 		$387K Hold
15,645
– – ﹤0.01% 1521
2020
Q1 		$217K Hold
15,645
– – ﹤0.01% 1654
2019
Q4 		$158K Hold
15,645
– – ﹤0.01% 2109
2019
Q3 		$142K Hold
15,645
– – ﹤0.01% 2136
2019
Q2 		$124K Hold
15,645
– – ﹤0.01% 2287
2019
Q1 		$195K Hold
15,645
– – ﹤0.01% 1996
2018
Q4 		$168K Buy
+15,645
New +$183K ﹤0.01% 1997

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

MetLife Investment Management's RCUS Position: Q1 2026 in Review

MetLife Investment Management increased its Arcus Biosciences (RCUS) stake by 3.2% in Q1 2026, buying an estimated $29.7K and bringing the position to 44,809 shares worth $968K. The position accounts for ﹤0.01% of the portfolio, ranked #1413.

MetLife Investment Management first reported a position in RCUS in Q4 2018 and has held it in 30 quarters since. The position peaked at $1.04M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • MetLife Investment Management held 44,809 shares of Arcus Biosciences worth $968K as of Q1 2026.
  • MetLife Investment Management bought 1,375 Arcus Biosciences shares in Q1 2026, an estimated $29.7K.
  • Arcus Biosciences made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1413 holding.
  • MetLife Investment Management first reported a position in Arcus Biosciences in Q4 2018 and has held it in 30 quarters since.
  • MetLife Investment Management's Arcus Biosciences position peaked at $1.04M in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.